Astellas Divests Prosidion’s DPP-IV Inhibitor Patent Assets to Royalty Pharma

By Heather Cartwright

Pharma Deals Review: Vol 2011 Issue 7 (Table of Contents)

Published: 12 Jul-2011

DOI: 10.3833/pdr.v2011.i7.1493     ISSN: 1756-7874

Section: Royalties

Fulltext:

Abstract

Japan’s Astellas Pharma has sold off the patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes held by its Prosidion subsidiary for US$609 M in cash...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details